Bandingkan Harga & Kinerja Paramita Bangun Sarana Tbk. (PBSA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Paramita Bangun Sarana Tbk. dan Organon Pharma Indonesia Tbk.: Paramita Bangun Sarana Tbk. diperdagangkan di Rp750 (kapitalisasi pasar 2,28 T, volume 24 jam 994 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Paramita Bangun Sarana Tbk. jauh lebih besar — sekitar 21,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| PBSA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 2,28 T | 104,4 M |
Volume | 994 rb | — |
Lot | 9,94 rb | — |
Perputaran | 754,23 jt | — |
Harga Rata-rata | 758,78 | — |
Nilai Transaksi | 754,23 jt | — |
Harga Ekuilibrium Indikatif | 750 | — |
Volume Ekuilibrium Indikatif | 56 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Paramita Bangun Sarana Tbk.
PT. Paramita Bangun Sarana Tbk (the Company) was established based on the Notarial Deed No. 33 of Lenny Janis Ishak, S.H., dated November 27, 2002.
Selengkapnya di halaman PBSA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
